BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15528138)

  • 1. Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients.
    Prigozhina TB; Elkin G; Gurevitch O; Morecki S; Yakovlev E; Khitrin S; Slavin S
    Blood Cells Mol Dis; 2004; 33(3):238-47. PubMed ID: 15528138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2004 Nov; 32(11):1110-7. PubMed ID: 15539090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation.
    Elkin G; Prigozhina TB; Slavin S
    Exp Hematol; 2004 Jun; 32(6):579-84. PubMed ID: 15183899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
    Soderling CC; Song CW; Blazar BR; Vallera DA
    J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach.
    Colson YL; Li H; Boggs SS; Patrene KD; Johnson PC; Ildstad ST
    J Immunol; 1996 Oct; 157(7):2820-9. PubMed ID: 8816385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation.
    Xu H; Chilton PM; Huang Y; Schanie CL; Yan J; Ildstad ST
    Transplantation; 2007 Apr; 83(7):954-63. PubMed ID: 17460568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
    Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
    Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment.
    Gammie JS; Li S; Colson YL; Demetris AJ; Neipp M; Ildstad ST; Pham SM
    Exp Hematol; 1998 Sep; 26(10):927-35. PubMed ID: 9728927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlethal conditioning for the induction of allogeneic chimerism and tolerance to islet allografts.
    Li H; Inverardi L; Molano RD; Pileggi A; Ricordi C
    Transplantation; 2003 Apr; 75(7):966-70. PubMed ID: 12698081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
    Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
    Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.
    Jankowski RA; Ildstad ST
    Hum Immunol; 1997 Feb; 52(2):155-61. PubMed ID: 9077564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete allogeneic hematopoietic chimerism achieved by in utero hematopoietic cell transplantation and cotransplantation of LLME-treated, MHC-sensitized donor lymphocytes.
    Hayashi S; Hsieh M; Peranteau WH; Ashizuka S; Flake AW
    Exp Hematol; 2004 Mar; 32(3):290-9. PubMed ID: 15003315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
    Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.
    Wu T; Sozen H; Luo B; Heuss N; Kalscheuer H; Lan P; Sutherland DE; Hering BJ; Guo Z
    Bone Marrow Transplant; 2002 Jun; 29(12):949-56. PubMed ID: 12098061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
    Li JM; Giver CR; Waller EK
    Exp Hematol; 2006 Jul; 34(7):895-904. PubMed ID: 16797417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.